A Novel Acyl-CoA: Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor, GSK2973980A, Inhibits Postprandial Triglycerides and Reduces Body Weight in a Rodent Diet-induced Obesity Model
Journal Title: Journal of Pharmaceutical Research International - Year 2017, Vol 18, Issue 6
Abstract
Background and Aim: Acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) is a key enzyme catalyzing the final step of triglyceride (TG) synthesis and is implicated in fat absorption and disposition. However, development of several DGAT1 inhibitors has been hampered due to unacceptable gastrointestinal (GI) tolerability observed in clinical trials. Our aim is to develop a novel, potent and selective DGAT1 inhibitor that reduces plasma TG levels and body weight with acceptable GI tolerability in a rodent model of obesity. Study Design: In vitro enzyme and cellular assays as well as in vivo experimental studies in mice and rat examining the effect of drugs on triglycerides, fecal fat, body weight and food intake. Place and Duration of Study: Virtual proof of concept, GSK USA & Cellzome, GSK Germany and Collaborative research, GVK, India between 2011-2017. Methodology: A radiometric assay of TG formation evaluated DGAT activity and a thermal shift assay determined target specificity. Fasted mice received an oral corn oil bolus to model hypertriglyceridemia. Intralipid administration in fasted rats was used to evaluate triglyceride clearance. Mice were fed a high fat diet to induce obesity. Results: Herein, we describe GSK2973980A as a novel, potent and selective DGAT1 inhibitor that reduced plasma TG levels in postprandial lipid excursion and impaired clearance studies in rodents and reduced body weight and food intake in obese mice. Interestingly, robust plasma TG reduction was accompanied by varying degrees of fecal lipid excretion. Alternate dosing via the subcutaneous route maintained a significant effect on plasma TG reduction with no altered fecal lipid excretion, suggesting GI tolerability may be modulated by limiting local GI exposure of DGAT1 inhibitors. Conclusion: Our data suggest that the impaired TG clearance model in the rat can be used to identify DGAT1 inhibitors with potentially better GI tolerability.
Authors and Affiliations
Sanjay Kumar, Vijaya G. Tirunagaru, Jennifer Ariazi, Amit Awasthi, Venkatesh Babu Jayaraman, Premkumar Arumugam, Mahesh Yanamandra, Sayan Mitra, Sudhir Tiwari, Raghuram S. Tangirala, Thilo Werner, Douglas Thomson, Giovanna Bergamini, Mui Cheung
Keywords
Related Articles
- EP ID EP313127
- DOI 10.9734/JPRI/2017/36835
- Views 97
- Downloads 0
A Comprehensive Review on Bioequivalence Studies in Human Subjects
Aims: Purpose of the current review was to provide information about the bioequivalence and the bioequivalence study steps in human subjects to conduct bioequivalence studies easily as well as to increase the use of alte...
Synthesis, Characterization and Evaluation of Biological Properties of Pyrazolo- and Oxazolo-pyridocarbazoles and Pyridoazacarbazoles as Potent Anti-microbial Agents
Aims: Fused carbazoles, azacarbazoles and quinolines are endowed with a wide array of pharmacological properties. Keeping these properties in the mind, the study was undertaken to seek structural modifications to generat...
A Study of Prophylactic Effect Against Diabetes of Two Ayurvedic Drugs ‘Jambadyarista’ and ‘Bohumutrantak Ras’ in Normal as well as Alloxan-induced Diabetic Rats
Aims: The present study was designed to evaluate the anti-diabetic as well as prophylactic activity of Jambadyarista and Bohumutrantak Ras in alloxan-induced diabetic rats. Study Design: Study the prophylactic and antig...
Development and Validation of HPLC Method for Analysis of Impurities of Fosfluconazole in Pharmaceutical Products
The contents of three related substances in fosfluconazole were determined by high performance liquid chromatography (HPLC). The limit of detection (LOD) of the impurity A (2-(2,4-difluorophenyl)-1,3-bis (1H-1,2,4-triazo...
Biocompatible and Biodegradable Chitosan / Clay Nanocomposites as New Carriers for Theophylline Controlled Release
Aims: Carrier polymeric materials based on chitosan and chitosan / montmorillonite crosslinked with glutaraldehyde were prepared and studied for their biocompatibility, nontoxicity, and biodegradability aiming their appl...